Abstract: The present invention provides for boron-containing wood preserving solutions and a method for their preparation. The wood preserving solutions of the invention are noncrystallizable at ambient temperatures and are prepared from a dispersion of a particulated sodium tetraborate, phosphoric acid and water by heating the dispersion at elevated temperatures and for a period of time sufficient to provide a clear solution. The particulated sodium tetraborate and phosphoric are present in the dispersion in a specific molar ratio of 5:3, said ratio being critical to achieving the noncrystallizable characteristic of the wood preserving solutions of the invention.

Abstract: A process and novel starting materials for the production of 17.alpha.-ethynyl-17.beta.-hydroxy-18-methyl-4,15-estradien-3-one of Formula I ##STR1## are disclosed. Novel 17-ketone starting materials have the Formula II ##STR2## wherein R is an alkyl residue of 1-3 carbon atoms and ##STR3## is the grouping ##STR4## wherein R' is an acyl group of up to 10 carbon atoms.

Abstract: This invention relates to a method for enhancing cell differentiation in malignant cells by exposing the cells to a 1.alpha.-hydroxylated vitamin D derivative characterized by a 17-side chain greater in length than the cholesterol or ergosterol side chains.The method finds application in the treatment of neoplastic diseases including leukemoid diseases and, specifically, leukemia.

Abstract: 1.alpha.,25-Dihydroxy-26,27-dimethylcholecalciferol represented by formula: ##STR1## This compound is prepared by irradiating 26,27-dimethylcholesta-5,7-diene-1.alpha.,3.beta.,25-triol with ultraviolet light, and is useful for the prevention or treatment of calcium pathobolism or osteoporosis.

Abstract: Novel soft steroid anti-inflammatory agents, said agents being esters or thioesters of 17.alpha.-alkoxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-carboxylic acids, pharmaceutical compositions containing said agents, novel chemical intermediates useful in the preparation of said agents and methods of administering same to mammals in the treatment of inflammation. Preferred compounds are the haloalkyl esters of 17.alpha.-alkoxy-11.beta.-hydroxyandrost-4-en-3-one-17.beta.-carboxylic acids.

Abstract: Known pregnane derivatives are prepared by esterificiation of known androstane derivatives to give new ester of Formula III ##STR1## wherein in each case symbolizes a single bond or a double bond,n is 1 or 2,R.sub.1 is hydrogen or methyl,R.sub.2 is hydrogen or formyl, andR.sub.3 is chlorine, hydroxy or an alkanoyloxy group of up to 6 carbon atoms,and reaction of the latter with Ag(I) and formic acid.

Abstract: C.sub.16 -unsaturated corticoids are readily transformed to the corresponding 16.alpha.-methyl-17.alpha.-hydroxy corticoids by use of a .DELTA..sup.17 (.sup.20)-20-silyl ether.

Abstract: Compounds of Formula I ##STR1## wherein the bond is a single bond or a double bond,X is hydrogen, fluorine, chlorine, or bromine,R.sub.1 is formyl, alkanoyl or alkoxyalkyl each of which contains 2-8 carbon atoms, or benzoyl, andY is chlorine, hydroxy, formyl, alkanoyloxy of 2-8 carbon atoms, or benzoyloxy,have valuable anti-inflammatory properties.

Abstract: The invention relates to a group of .DELTA..sup.4 - and .DELTA..sup.5(10) -oestrene derivatives having an alkyl(1-4 C) substituent in position 6 or 7, an oxy substituent in position 17.beta. and optionally an oxo- or oxy-substituent in position 3 and a hydrocarbyl(1-4 C) group in position 17.alpha., for use as immunomodulator. The compounds are in particular suitable for therapeutic use in the treatment of auto-immune diseases.

Abstract: The invention relates to a method of combatting fungal diseases with the aid of(a) an oomycetes controlling fungicide of formula I ##STR1## wherein R.sub.1, R.sub.2, independently, are H or CH.sub.3R.sub.3 is H, Cl, Br,X is CH(CH.sub.3)COOCH.sub.3, 2-oxo-tetrahydrofuran-3-yl, 2-oxo-tetrahydrothien-3-yl or 2-oxo-1,3-oxazolidin-3-yl andY is Ch.sub.2 OCH.sub.3, 2-furyl, benzyl, CH.sub.2 Cl, cyclopropyl or 3-isoxazolyl,in association with(b) Anilazine of formula II ##STR2## in admixture or separately in a fungicidally effective aggregate amount, and optionally other fungicides, and to fungicidal compositions comprising such fungicides.

Abstract: Novel 10-substituted steroids of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl and substituted alkyl of 1 to 8 carbon atoms, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl of 2 to 8 carbon atoms, aryl and substituted aryl, aralkyl and substituted aralkyl, protected hydroxy, optionally esterified carboxy, --NH.sub.2, protected amino, mono and di-alkyl amino of 1 to 4 alkyl carbon atoms, halogen and trialkylsilyl, R.sub.2 is methyl or ethyl, R.sub.6 and R.sub.7 together with the carbon atoms to which they are attached form cyclopropyl or R.sub.6 is hydrogen and R.sub.7 is R.sub.1, R.sub.1 is selected from the group consisting of hydrogen, alkyl and substituted alkyl of 1 to 6 carbon atoms, acetylthio and alkenyl, substituted alkenyl, alkynyl and substituted alkynyl of 2 to 6 carbon atoms, X is optionally acylated or etherified hydroxyl and Y is selected from the group consisting of hydrogen, R.sub.4, --CH.sub.2 --CH.sub.2 COOM and --CH.sub.2 --CH.sub.

Abstract: A process for the preparation of 16,17 acetals of pregnane derivatives by trans-ketalization of 16,17-acetonides is described.In the instance of the preparation of 16.alpha.,17.alpha.-butylidenedioxy-11.beta.,21-dihydroxypregna-1,4-diene- 3,20-dione, a compound having useful therapeutic properties, known also as budesonide, it is possible to obtain the more active epimer with high selectivity and remarkable economic advantages in comparison with the known methods.New 16,17 acetals of pregnane derivatives, which can be prepared by the method of the invention, are also described.

Abstract: This invention concerns a method of treatment using 1,4-dihydropyridine derivatives having the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R is aryl or heteroaryl;R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl;Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --;X is a 5 or 6 membered nitrogen containing aromatic heterocyclic ring which may optionally be substituted by one or more C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, CN, --N(R.sup.3).sub.2, (CH.sub.2).sub.m CO.sub.2 H, (CH.sub.2).sub.m CO.sub.2 (C.sub.1 -C.sub.4 alkyl) or (CH.sub.2).sub.m CON(R.sup.3).sub.2 groups wherein each R.sup.3 is independently H or C.sub.1 -C.sub.4 alkyl and m is 0 or 1;and n is 1 to 3 when X is linked by a ring carbon atom or 2 or 3 when X is linked by a ring nitrogen atom.

Abstract: This invention relates to bird repellent. In particular, this invention relates to new compositions for protecting surfaces from birds and to repelling birds from various areas. It is also directed to a method of preventing birds from remaining in selected areas.

Abstract: A process for controlling hyperlipidemia in mammals is disclosed. In this process a mammal suffering from hyperlipidemia is treated with a hyperlipidemia controlling effective amount of a compound having the structural formula ##STR1## wherein R.sup.1 is mercapto, amino, hydroxy or C.sub.1 -C.sub.4 alkylthio; R.sup.2 is amino, hydroxy or mercapto; and R.sup.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.7 -C.sub.9 alkoxyphenyl or C.sub.7 -C.sub.9 aralkyl.In another aspect of the present invention a pharmaceutical composition comprising the above compound in combination with a pharmaceutically acceptable carrier therefor is provided.

Abstract: The invention provides a novel vitamin D derivative, 1.alpha.,25-dihydroxy-22Z-dehydrovitamin D.sub.2.The compound is characterized by unexpectedly high ability to raise serum calcium levels. The compound could therefore, find ready application as a substitute for vitamin D or its metabolites in the treatment of metabolic bone diseases or in other of their known applications.

Abstract: A process for controlling hyperlipidemia in mammals is disclosed. In this process a hyperlipidemia controlling effective amount of a compound having structural formula: ##STR1## where R.sup.1 is hydrogen, oxo, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl; R.sup.2 is hydrogen or oxo; and R.sup.3 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkanoyl, C.sub.2 -C.sub.6 carboxyalkyl, phenyl, benzyl or phenyl substituted with C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkoxy or halo is applied to mammals. A pharmaceutical composition comprising the above class of compounds having the meanings given herein and a pharmaceutical carrier therefor is also taught.

Abstract: 1'-Sulfonylsteroido[3,2-c]pyrazoles, for example, (5.alpha.,17.alpha.)-1'-(methylsulfonyl)-1'H-pregn-20-yno[3,2-c]pyrazol-17 -ol, which are useful as antiandrogenic agents, and processes for preparation, method of use and compositions thereof are disclosed.

Abstract: A valuable alternative antifungal antibiotic, for treatment especially of candidiasis, particularly vaginal candidiasis, is proposed. The antibiotic is a bile acid or simple derivative (salt or conjugate) thereof. Cholic, deoxycholic, chenodeoxycholic and lithocholic acid are preferred bile acids. The antibiotic is formulated for topical application. It can be used in association with an anti-inflammatory steroid for the treatment of fungal infections of the skin. It is also proposed to inhibit fungal growth in a variety of pharmaceutical compositions (containing some other active ingredient) by including in the composition, or coating a tablet, pill or capsule with, the bile acid component.

Abstract: Estriol esters of Formula I ##STR1## wherein R, in each case, means the residue of a monocarboxylic acid of 2-10 carbon atoms.The novel estriol esters surpass estriol in strength and duration of estrogen effect.